Esophageal, gastroesophageal junction, and gastric cancers are underpublicized but are frequently lethal, and gastroesophageal junction adenocarcinomas are increasingly common diseases in the United States and around the world. Although often grouped together in studies of chemotherapy, clear distinctions can be made in the locoregional therapy of these diseases. Esophageal squamous cell carcinomas may be treated with surgery or radiation with concurrent chemotherapy, whereas esophageal adenocarcinomas and gastroesophageal junction adenocarcinomas are often treated with all three treatment modalities. Over the past several years, it has become increasingly evident that gastric cancer is a disease that is potentially sensitive to chemotherapy. In the perioperative setting—at least in the Western world—chemotherapy and sometimes radiation are applied. However, the optimal chemotherapy for advanced gastric or esophageal cancer remains unsettled, and there is no single standard regimen. Several new chemotherapy agents have demonstrated activity in these diseases, but the best chemotherapy remains to be determined. This paper will review the role of chemotherapy in gastroesophageal cancers.
In the United States, gastric and esophageal cancers are not considered as great a public health and treatment priority as more common malignancies such as breast, lung, prostate, or colorectal cancer. Worldwide, however, gastroesophageal malignancies are a leading cause of cancer-related mortality. An estimated 22,280 new cases of gastric cancer were diagnosed in the US in 2006, with an estimated 11,430 deaths caused by the disease. Esophageal cancers are even less common, with an estimated 14,550 new cases diagnosed in 2006, and 13,770 resultant deaths. Worldwide, gastric cancers were the fourth most commonly diagnosed malignancy (933,293 patients) and second leading cause of cancer-related mortality (698,030) in 2002, according to GLOBOCAN statistics. In some East Asian nations, gastric cancer is the leading cause of cancer-related mortality. Esophageal cancers constituted the eighth leading cause of cancer-related mortality in 2002, resulting in 385,877 deaths. In addition, gastroesophageal junction cancers are among the most rapidly rising malignancies in the United States and the Western world. Thus, further development of effective therapies for these diseases is urgently needed.
Histology and Treatment
Historically, therapeutic approaches to gastric and esophageal cancers have been considered separately, with limited consideration of (and, therefore, little data on) gastroesophageal junction (GEJ) carcinomas. When reviewing the therapy for gastric, esophageal, and GEJ cancers, the histology of the malignancy is an important consideration. Until the past several decades, in the United States, the majority of esophageal cancers were squamous cell carcinomas, often of the upper and mid-esophagus, caused primarily by exposure to tobacco and alcohol. However, with declining use of tobacco and an increase in obesity and reflux disease, distal esophageal, gastroesophageal junction, and gastric cardia adenocarcinomas have been on the rise.
It is unclear whether the differences among these diseases reflect differences in etiologies, histologies, or anatomy. Because of anatomic constraints, the surgery for esophageal cancer is distinct from that for gastric and gastroesophageal cancers. Perhaps as a result of this, the approaches to multimodality therapy also differ for esophageal and gastric cancers, as we will discuss later.
Chemotherapy in Metastatic Gastric Cancer
In attempting to assess the activity of chemotherapy in advanced gastric and esophageal cancers, we will first review the data in the metastatic setting. There are no definitive data (in the form of randomized clinical trials) regarding the activity of chemotherapy in esophageal cancer. Typically, assessments of activity of chemotherapy for squamous cell carcinomas of the esophagus have been extrapolated from findings in head and neck cancers. Recently, patients with adenocarcinomas of the esophagus have been enrolled in clinical trials for gastric cancer. For both disease types, there is no single standard therapy for the management of metastatic disease. This element of the review will focus on the available data for metastatic gastric and esophageal adenocarcinomas.
Unlike some malignancies, such as breast cancer and acute leukemias, where the antitumor activity of chemotherapy has been deemed to be so evident as not to require clinical trials to demonstrate efficacy, three clinical trials have been performed in metastatic gastric cancer, comparing chemotherapy to supportive care alone. Although these studies were small and evaluated different fluoropyrimidine-based chemotherapeutic regimens, the results were consistent, with a statistically significant but clinically limited improvement in median survival, from 3-5 months with supportive care, to 8-12 months with chemotherapy (Table 1).[4-6]
Fluoropyrimidines and Single-Agent Chemotherapy
As with colorectal cancers, fluoropyrimidines historically have been the standard and core of therapy for advanced gastric cancers. Indeed, several phase III clinical trials have been performed comparing single-agent fluorouracil (5-FU) to combinations of chemotherapy.[7-10] The results with 5-FU have been disappointing, with response rates of 11% to 26%, and median survivals of 6 to 8 months.[7-11] Unfortunately, although response rates were greater with combination regimens such as cisplatin/5-FU or mitomycin/5-FU, investigators found no survival benefit for patients treated with combination chemotherapy (Table 2). Both Cullinan and Ohtsu reported significant improvements in progression-free survival, albeit at the cost of greater myelotoxicity, nausea, vomiting, and diarrhea.[8,10]
Based on these results, 5-FU may be considered a reasonable therapy, producing an overall survival similar to the cisplatin/5-FU combination, with less toxicity. Because of the greater progression-free survival, some investigators, including those at the US Food and Drug Administration (FDA), believe that combination chemotherapy—in particular 5-FU/cisplatin-based therapy—represents the standard therapy for advanced gastric cancer. This view has been buttressed by a recent meta-analysis.
Nonetheless, as combination chemotherapy has not definitively been proven to be superior to single-agent 5-FU, a reasonable avenue of exploration is to investigate fluoropyrimidines or other antifolates that are either better tolerated or easier to administer. In particular, capecitabine (Xeloda) has been studied in phase II trials and has been reported to produce response rates of about 20% to 25%, with modest toxicity, similar to studies in colorectal cancer.[13,14] Another oral fluoropyrimidine, S-1, which is combined with inhibitors of dihydropyrmidine dehydrogenase and pyrimidine phosphoribosyl transferase to optimize the activity and minimize the toxicity of the compound, is also undergoing investigation in gastric cancer.
The multitargeted antifolate pemetrexed (Alimta) has undergone limited evaluation in gastric cancer in patients who also received folic acid. The single-agent activity of pemetrexed was similar to that of other single agents, with a 21% response rate in 38 patients, and a median survival of 7.8 months. Therapy was well tolerated in these patients, with the most common toxicity being asymptomatic neutropenia.
As noted in Table 3, other third-generation chemotherapy agents, including docetaxel (Taxotere),[17,18] paclitaxel, and irinotecan (Camptosar), have demonstrated modest single-agent anticancer activity in this setting with acceptable toxicity, resulting in further investigations of these agents, in various combinations, in phase II and III studies.
Dr. Hwang is an investigator, speaker, and consultant for Sanofi-Aventis, Genentech, Amgen, and Pfizer, and is an investigator for Bristol-Myers Squibb.
1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006.
2. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150, 2006.
3. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991.
4. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993.
5. Pyrhonen S Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995.
6. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997.
7. Kim NK, Park YS, Heo DS, et al: A phase II randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813, 1993.
8. Cullinan SA, Moertel CG, Wieand HS, et al: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 12:412-416, 1994.
9. Tebbutt NC, Norman A, Cunningham D, et al: A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophagogastric cancer. Ann Oncol 13:1568-1575, 2002.
10. Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplati versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group study (JCOG 9205). J Clin Oncol 21:54-59, 2003.
11. Bouche O, Raoul JL, Bonnetain F, et al: Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: A Federation Francophone de Cancerologie Digestive Group study-FFCD9803. J Clin Oncol 22:4319-4328, 2004.
12. Wagner AD, Growthe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909, 2006.
13. Hong YS, Song SY, Lee SI, et al: A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344-1347, 2004.
14. Koizumi W, Saigenjii K, Ujie S, et al: A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64:232-235, 2003.
15. Chollet P, Schoffski P, Weigang-Kohler K, et al: Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39:1264-1270, 2003.
16. Bajetta E, Celio L, Buzzoni R, et al: Phase II study of pemetrexed disodium (ALIMTA) adminstered with oral folinic acid in patients with advanced gastric cancer. Ann Oncol 14:1543-1548, 2003.
17. Sulkes A, Smyth J, Sessa C, et al: Docetaxel in advanced gastric cancer: Results of a phase II trial. Br J Cancer 70:380-383, 1994.
18. Einzig AI, Neuberg D, Remick SC, et al: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293. Med Oncol 13:87, 1996.
19. Yamada Y, Shirao K, Ohtsu A, et al: Phase II trial of paclitaxel by three tour infusión for advanced gastric cancer with short premedication for prophylaxis against paclitaxel associated hypersensitivity reactions. Ann Oncol 12:1133-1137, 2001.
20. Kohne CH, Catgane R, Klein B, et al: Irinotecan is active in chemonaive patients with metastatic gastric cancer: A phase II multicentric trial. Br J Cancer 89:997-1001 2003.
21. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin, versus etoposide, leucovorin, and fluourouracil and versus infusional fluoruracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657, 2000.
22. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouruacil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997.
23. Ross P, Nicolson M, Cunningham D, et al: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996-2004, 2002.
24. Ajani JA, Fodor MB, Tjuladi SA, et al: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 23:5660-5667, 2005.
25. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J Clin Oncol 24:4991-4997, 2006.
26. Kim JG, Sohn SK, Kim DH, et al: Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 68:190-195, 2005.
27. Giordano KF, Jatoi A, Stella PJ, et al: Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 19:652-656, 2006.
28. Sumpter K, Harper-Wynn C, Cunningham D, et al: Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 92:1976-1983, 2005.
29. Cunningham D, Rao Starling T, et al: Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial (abstract LBA4017). J Clin Oncol 24(18S):182s, 2006.
30. Kang Y, Kang WK, Shin DB, et al: Randomized phase III trial of capecitabine /cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results (abstract LBA4018). J Clin Oncol 24(18S):183s, 2006.
31. Louvet C, Andre T, Tigaud JM, et al: Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543-4548, 2002.
32. DeVita F, Orditura M, Matano E, et al: A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 9:1644-1649, 2005.
33. Santini D, Graziano F, Catalano V, et al: Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: Results of a phase II trial. BMC Cancer 6:125, 2006.
34. Jatoi A, Murphy BR, Foster NR, et al: Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:29-34, 2006.
35. Ajani JA, Baker J, Pisters PWT, et al: CPT-11 plus cisplatin in patients with advanced untreated gastric or gastroesophageal junction carcinoma. Results of a phase II study. Cancer 94:641-646, 2002.
36. Pozzo C, Barone C, Szanto J, et al: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: Results of a randomized phase II study. Ann Oncol 15:1773-1781, 2004.
37. Dank M, Zaluski J, Barone C, et al: Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st line advanced gastric cancer patients (abstract 4003). J Clin Oncol 23(16S):308s, 2005.
38. Gadgeel SM, Shields AF, Heilbrun LK, et al: Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 26:37-41, 2003.
39. DeLange SM, Van Groeningen CJ, Kroep JR, et al: Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 15:484-488, 2004.
40. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24:4922-4927, 2006.
41. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al: Predictive factors for outcomes in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24:1612-1619, 2006.
42. Adelstein DJ, Rybicki LA, Carroll MA, et al: Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction cancer (abstract 4054). J Clin Oncol 23(16S):321s, 2005.
43. Van Groeningen C, Richel D, Giaccone G, et al: Gefitinib phase II study in second-line treatment of advanced esophageal cancer (abstract 4022). J Clin Oncol 22(14S), 2004.
44. Shah MA, Ramanathan RK, Ilson, DH, et al: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201-5206, 2006.
45. Herskovic A, Martz K, Al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-1598, 1992.
46. Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281:1623-1627, 1999.
47. Bosset J-F, Gignoux M, Triboullet J-P, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell carcinoma of the esophagus. N Engl J Med 337:161-167, 1997.
48. Urba SG, Orringer MB, Turrisi A, et al: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313, 2001.
49. Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esohpagus. J Clin Oncol 23:2310-2317, 2005.
50. Bedenne L, Michel P, Bouche O, et al: Randomized phase III trial in locally advanced esophageal cancer: Radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102) (abstract 519): Proc Am Soc Clin Oncol 21:130a, 2002.
51. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996.
52. Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 11:1441-1447, 1993.
53. Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A sutyd of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomai dell'Apparato Digerente). Ann Oncol 11:837-847, 2000.
54. Shimada K, Ajani JA: Adjuvant therapy for gastric carcinoma patients in the past 15 years: A review of western and oriental trials. Cancer 86:1657-1668, 1999.
55. MacDonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001.
56. Wilke H, Preusser P, Fink U, et al: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7:1318-1326, 1989.
57. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006.